BRN 1723530 en es it fr

BRN 1723530 Brand names, BRN 1723530 Analogs

BRN 1723530 Brand Names Mixture

  • No information avaliable

BRN 1723530 Chemical_Formula


BRN 1723530 RX_link

No information avaliable

BRN 1723530 fda sheet

BRN 1723530 msds (material safety sheet)$FILE/English.pdf

BRN 1723530 Synthesis Reference

No information avaliable

BRN 1723530 Molecular Weight

133.104 g/mol

BRN 1723530 Melting Point

230 oC

BRN 1723530 H2O Solubility

4.5 g/l

BRN 1723530 State


BRN 1723530 LogP

-0.67 +/- 0.36

BRN 1723530 Dosage Forms

Capsules and powder

BRN 1723530 Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

BRN 1723530 Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

BRN 1723530 Absorption

Absorbed from the small intestine by an active transport process

BRN 1723530 side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

BRN 1723530 Patient Information

No information avaliable

BRN 1723530 Organisms Affected

Humans and other mammals